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m8031 ImpactofCilostazolonIntimalProliferationFollowingDirectionalCoronsry Atheractomy: A
Proapeotive Randomized Trial
E. Tsuchikane, O. Katoh, S. Sumitsuji, A. Fukuhara, N. Awata,
T. Kobsyashi. Osaka Medical Center for Cancer and Cardiovascular
Diseases, Osaka, Japan
Cilostezol, a new synthetic platelet-aggregation inhibitor, has a specific in-
hibitory action on cyclic AMP phosphodiesterese. It inhibits intimal prolifera-
tion of injurad carotid arIety of rats orstented iliac artery of dogs asa result of
cyclic AMP accumulation in smooth muscle cells. The aim of this study was to
determine the effed of cilostazol on intimal proliferation following directional
coronav atherectomy. Thirly nine patients with lesions suitable for DCAwere
randomized to a cilostazol (C) (200 mg/day) group (20 pts) or an aspirin (A)
(250 m~day) group (19 pts). Medication was startad 1 week before DCA
and wee continued to follow-up in all patients. Serial QCA and IVUS was
performed at pre-, post-DCA and follow-up (Fu). Mean Fu duration was 209
+38 days. QCA was performed by a Cardiovascular Measurement System.
Angiographic restenosis was defined as a Y. diameter stenosis ?50~0 at Fu.
Vessel area (VA) and plaque area (PA) were measured serially at the nar-
rowest site in the lesion at pre-DCA. QCA and QCU were performed blindly.
QCA and QCU data were as follows:
OCA preRD preMLD postMLD Fu MLD Fu % DS Restenosis
C group 3.04 mm 0.89 mm 2.81 mm 2.33 mm* 25Yo* o%*
A group 3.16 mm 0.83 mm 2.77 mm 1.61 mm 41Y0 26%
QCU ‘preVA postPA post‘A PA FU PA Fu % PA dPA
C group 15.5 mmz 8.2 mm2 47% 6.7 mm2 56”h* 0.5 mm2
A group 16,0 mm2 9.1 mm2 46% 10.9 mm2 s4”/0 1.6 mm2
*p< 0.05 vs A group (RD = rsference diameter, MLD = minimallumen diameter, DS =
diameter atenosia dPA = Fu PA-postPA)
Conclusion: CilostezOl has an inhibitory effect on intimal proliferation
following DCA and significantly reduces restenosis.
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Surraundina Palmsz-Schatz Stents is Associated——.. -
with Procedural Vassal Wall Injury
R. Hoffmann, G.S. Mintz, R. Mehran, K.M. Kent, A.D. Pichard, L.F. Satler,
J.J. Popma, J.R. Laird, T.A. Bucher, G. Bucher, M.B. Leon. Washin9fon
Hospital Center, Washington, DC, USA
Previous serial intravascular ultrasound studies have shown that Palmaz-
Schatz stent implantation induces both in-stent and peri-stent tissue pro-
liferation. To determine whether these are a function of vessel wall injury,
we studied 90 native vessel lesions using post-intervention and follow-up
(F/U) ultrasound {measurement of arterial, stent, and lumen areas (mm2)
and calculation of% in-stent intimal hyperplasia (Y. IH = stent-lumen/stent)
area, peri-stent plaque (arterial-stent) area, and pari-stent tissue growth
(Aperi-stent plaque area)} and quantitative angiogrephy (measurement of
loss index = late losa/acute gain). An injury score (IS) was constructed from
procedural variables: O (adjunct PTCA pressure s 16 atm & balloon:artery
ratios 1.1), 1 (adjunct PTCA pressure =-16atm or balloon:affefy ratio >1.1,
and 2 (adjunct PTCA pressure >16 atm & balloon:attery ratio >1 .1).
Is= o Is= 1 Is= 2 IIANOVA
(N= 17) (N =5S) (N= 15)
FIU lumensrea 3.7* 3.1 2.s & 2.2 1.3+ 0.6 0.0037
F/U ‘A IH aras 51 l 22 54& 21 61 &14 0.0627
Peri-stenttiseue growih 1.1 * 1.2 1,5 * 1.4 2.5 + 1.1 0.0322
Lees index 0.7* 0.4 0.9+0.4 1.3 + 1.4 0.0290
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ACEInhibition Accelerates Endothelial Regrowth in
Vivo: A Possible Explanation for the Benefit
Observad with ACE.inhibitors Following Arterial
Injury
E. Van Belle, T. Meurice, F.O.Tie, D. Corseaux, B. Dupuis, E.P. Mc Fadden,
J.-M. Lablanche, C. Bauters, M.E. Bertrand. Department of Cardiology,
UniversifyofLi//e, France, University of Texas,San Antonio, TX, USA
Recent in vitro studies suggast that angiotensin converting enzyme (ACE)
inhibitors stimulate endothelial cell proliferation and migration. Tha presant
study was designed to test the hypothesis that an ACE inhibitor may accel-
erate endothelial regrowth in vivo. Twenty four New Zealand White rabbits
were randomized to receive orally placebo or the ACE inhibitor perindopril (1
mg/kg/day)and underwent balloon denudation of one iliac artery 7 days later.
At the time of vascular injury plasma ACE activity waa effectively blocked in
ACE inhibitor treated animals compared to controls (5.2 &2.6 mU/mLvereus
93.7 + 6.4 mU/mL; P < 0.0001). Twenty eight days after injury, animals were
sacrificed and endothelial regrowth was evaluated by planimetric quantifi-
cation of the non-stained Iuminal surface following injection of Evans blue.
Reendothelialization wassignificantly greater in ACE inhibitortreated animals
than in controls (131 =!=9 mmz versus 69 +=8 mm2; P < 0.001). Analyais
of percent reendothelialization, defined as the ratio of the reendothelializsd
area divided by the initially denuded area (x 100), confirmed these results
(73 +3% versus 37 + 3%, P < 0.0001). These results were validated by
performing scanning electron microscopy and specific immunostaining for
endothelial cells (PECAM-1).
Cone/usions:These data provide the first in vivodemonstration that ACE
inhibitors accelerate endothelial regrowth after arterial injury.This effect may
contribute to the benefit obsewed with ACE inhibition following arterial injury.
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m8034 Radiotherapy Raducea Coronary Reatenoala: Late
Follow-UP
P.S.Teiretein,V. Massullo, S. Jani, G.S. Mintz, R.J. Russo, R.A. Schafz,
S. Steuterman, N.B. Morris, E.M. Guameri, M.B. Leon, P.Tripuraneni,
J.J. Popma. Scr7ppsC/inicand Research Foundation, La Jolla, CA, USA,
WashingtonHospital Centec Washington, D.C., USA
The SCRIPPS (Scripps Coronary Radiation to Inhibit Proliferation Post-
Stenting) trial is a double-blind, randomized, placebo-controlled trial of in-
tracoronaV gamma (lr-192) radiation plus stenting in pts with previous
restenosis. Fifty-five pts were enrolled from 3/24/95 to 12/22f95. Angio-
graphic follow-up (FU) was obtained on all eligible pte at 8.7 + 2.2 mos
(range 2-14). Independent, quantitative core lab analysis revealad:
lr-192 (n = 24)t Plscebo (n = 28)* P
Reference dismeter (mm) 2.S8 2.7S NS
% stenosis,pre 61.5 62.2 NS
% stenosis,post 2.e2 2.S7 NS
% stenosis,FU 17 37 0.01
FU lumendiameter 2.43 1.85 0.02
Late lumen10ss(mm) 0.3s 1.03 0.02
Late lossindex(mm) 0.12 0.60 0.002
tl s~entthrombosis;1 angiOgrsmUnanalyzable, $1 csrdiscdeath at 8 montha
Leteclinicalfollow-up isavailablefor IOO%of ptsat 12.3 +2.9mos (range
8-18). There wee 1 cardiac death (placet@ and 1 stent thrombosis (lr-192)
resulting in non-Q-wave Ml. Target lesion revascularization waa required in
16 (29Yo)pts (k-192 vs. placebo to be disclosed at presentation).
Intrecoronary radiotherapy with k-192 plus etenting effectively inhibits
Iuminal renarrowing in pts with restenosis.
Peri-stent tissue growth correlated with in-stent IH (P= O.0121).Both peri-
stent tissue growth (1.9+ 1.4 vs 1.3 + 1.0, p = 0.0840) and in-stent IH (4.0 *
21. vs 1.2+ 0.7, p < 0.0001) were greater in restenoticthan in non-reetenotic
stents. We conclude: Deep vessel wall injury as a result of oversized etents
implanted at high (>16 atm) pressures results in exaggerated in-stent and
peri-stent tissue growth. This manifests ae reduced F/U lumen areas and
increased in-stent restenosis.
